FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery
RegulatoryapprovedJemperliPositive
AI Analysis
Summary
The FDA granted accelerated approval for a new use of Jemperli (dostarlimab-gxly) in locally advanced rectal cancer. The immunotherapy may allow some patients to avoid chemotherapy, radiation and surgery.
Outcome Details
FDA granted accelerated approval for a new use of Jemperli (dostarlimab-gxly) in locally advanced rectal cancer, which may allow some patients to avoid chemotherapy, radiation and surgery.
Importance:8/10
Sentiment:
0.80
FDA approvalaccelerated approvalimmunotherapyrectal canceroncologyPD-1label expansion
Related Companies
Read the original article
Published by FDA Drugs (New Approvals & NDA) on October 19, 2026 4:54 PM